Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an antistaphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: preplanned analysis from CAMERA2

JZY Soo; TP Lim; JJY Ho; SYC Tong; DC Lye; JS Davis; ALH Kwa; D Yahav; A Sud; J Owen Robinson; J Nelson; S Archuleta; MA Roberts; A Cass; DL Paterson; H Foo; M Paul; SD Guy; AR Tramontana; GB Walls; S McBride; N Bak; N Ghosh; BA Rogers; AP Ralph; J Davies; PE Ferguson; R Dotel; GL McKew; TJ Gray; NE Holmes; S Smith; MS Warner; S Kalimuddin; BE Young; N Runnegar; DN Andresen; NA Anagnostou; SA Johnson; MD Chatfield; AC Cheng; VG Fowler; BP Howden; N Meagher; DJ Price; SJ van Hal; MVNO Sullivan

Journal article

Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an antistaphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: preplanned analysis from CAMERA2

JZY Soo, TP Lim, JJY Ho, SYC Tong, DC Lye, JS Davis, ALH Kwa, D Yahav, A Sud, J Owen Robinson, J Nelson, S Archuleta, MA Roberts, A Cass, DL Paterson, H Foo, M Paul, SD Guy, AR Tramontana, GB Walls Show all

Clinical Microbiology and Infection | Elsevier BV | Published : 2026

DOI: 10.1016/j.cmi.2026.01.032

Abstract

Objective Combination antibiotic therapy may improve treatment success for bacterial infections, but bacterial strain-to-strain variability in synergy and its clinical impact remains unclear. This study evaluated whether positive in vitro interactions (synergy or additivity) between vancomycin or daptomycin and a β-lactam in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections are associated with improved clinical outcomes in the Combination Antibiotic for Methicillin Resistant Staphylococcus aureus (CAMERA2) trial. Methods In this post hoc analysis of the multicentre randomized CAMERA2 trial, adults with MRSA bacteraemia were randomly assigned to standard care (vancomyc..

View full abstract